You are here:

caffeine Citrate 20mg/ml solution for infusion and oral solution (Peyona)

Advice

following a full submission:

caffeine citrate (Peyona®) is accepted for use within NHS Scotland.

Indication under review: treatment of primary apnoea of premature newborns.

In premature infants with apnoea of prematurity, caffeine citrate significantly reduced apnoeic episodes compared with placebo.  A long-term placebo-controlled study demonstrated a reduced risk of disabilities relevant to these infants.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of caffeine citrate (Peyona®).  This SMC advice is contingent upon the continuing availability of the PAS or an equivalent or lower list price in NHS Scotland.

Drug Details

Drug Name: caffeine Citrate 20mg/ml solution for infusion and oral solution (Peyona)
SMC Drug ID: 814/12
Manufacturer: Chiesi Limited
Indication: Treatment of primary apnoea of premature newborns.
BNF Category:
Sub Category: 3.5 Respiratory stimulants and pulmonary surfactants
Submission Type: Full submission
Status: Accepted
Date Advice Published: 9 September 2013

Archived Advice

Non submission 8 October 2012

Back